Cart (0 Items)
Your cart is currently empty.
View ProductsExplore Our Ready-to-Use Stable Cell Pools for Therapeutic Antibody Development
Accelerate your path to therapeutic antibodies with our portfolio of well-characterized, high-expression Stable Cell Pools.
Whether you are advancing biosimilar programs with gold-standard antibodies or driving the development of novel biologics, our off-the-shelf monoclonal cell pools are optimized for high-speed monoclonal development and bulk production!
Ask for your fast monoclonal development or for a bulk quantity of therapeutic antibody below !
Need a protein or another antibody expressing cell line ?
Discover our custom cell line services
Featured Stable Cell Pools:
Each Stable cell pools is developed using our proprietary expression platform and quality-controlled
to ensure robust and consistent antibody production.
| Name of therapeutic (pool) | Target | Isotype | Yield | Therapeutic Area |
|---|---|---|---|---|
| Cetuximab | hEGFR | IgG1 | Between 5g/L and 10g/L | Oncology |
| Rituximab | MS4A1 | IgG1 | Between 5g/L and 10g/L | Immunotherapy |
| Ramucirumab | VEGFR-2 | IgG1Kappa | Between 5g/L and 10g/L | Oncology |
| Infliximab | TNF-alpha | IgG1 | Between 5g/L and 10g/L | Inflammation |
| Adalimumab | TNF-alpha | IgG1 | Between 5g/L and 10g/L | Inflammation |
| Nivolumab | PD-1 | IgG4 | Between 5g/L and 10g/L | Immunotherapy |
| Bevacizumab | VEGF | IgG1 | Between 5g/L and 10g/L | Oncology |
| Panitumumab | EGFR | IgG2-kappa | Between 5g/L and 10g/L | Oncology |
| Ustekinumab | Human IL-12 IL-23 | IgG1 | Between 5g/L and 10g/L | Inflammation |
| Ranibizumab | VEGF | FabG1 | Between 5g/L and 10g/L | Oncology |
| Ipilimumab | CTLA-4 | IgG1Kappa | Between 5g/L and 10g/L | Immunotherapy |
| Natalizumab | ITGA4, CD49d | IgG4-kappa | Between 5g/L and 10g/L | Inflammation |
| Daclizumab | IL2RA | IgG1-kappa | Between 5g/L and 10g/L | Inflammation |
| Palivizumab | RSV | IgG1-kappa | Between 5g/L and 10g/L | Virology |
| Belimumab | TNFSF13B, CD257 | IgG1-lambda | Between 5g/L and 10g/L | Immunology |
| Denosumab | RANKL | IgG2Kappa | Between 5g/L and 10g/L | Developmental Biology |
Need to test the efficiency of your new drug candidate ?
Discover our biosimilar library
Why Choose Our Stable Cell Pools?
High-yield & scalable CHO cell systems
Our cell lines are based on optimized CHO expression systems to ensure high productivity and seamless scalability, from lab-scale testing to large-scale bioproduction.
Expression of clinically validated monoclonal antibodies
Each stable cell line expresses a monoclonal antibody referenced in clinical applications, ensuring biological relevance and reliable benchmarking for biosimilar development.
Quality controlled & sequence verified
All cell lines undergo strict QC procedures, including sequence verification, stability checks, and expression profiling to guarantee batch-to-batch consistency.
No royalties
ProteoGenix has selected royalty-free cell lines and owns its proprietary cell line, allowing you complete freedom for the future of your project.
Ideal for biosimilar R&D, validation, or early-stage production
Designed for flexibility, our cell lines are suited for analytical method development, comparative studies, and pilot-scale manufacturing in biosimilar pipelines.